Neuronetics, Inc. (NASDAQ:STIM - Get Free Report) EVP William Andrew Macan sold 14,120 shares of Neuronetics stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $1.65, for a total transaction of $23,298.00. Following the transaction, the executive vice president owned 673,561 shares of the company's stock, valued at $1,111,375.65. The trade was a 2.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
William Andrew Macan also recently made the following trade(s):
- On Tuesday, February 10th, William Andrew Macan sold 3,485 shares of Neuronetics stock. The stock was sold at an average price of $1.55, for a total value of $5,401.75.
Neuronetics Stock Down 3.5%
STIM stock opened at $1.38 on Thursday. The business has a 50 day moving average of $1.69 and a 200 day moving average of $2.38. The firm has a market cap of $94.52 million, a PE ratio of -1.68 and a beta of 0.79. Neuronetics, Inc. has a twelve month low of $1.25 and a twelve month high of $5.92. The company has a quick ratio of 2.09, a current ratio of 2.24 and a debt-to-equity ratio of 2.09.
Analyst Upgrades and Downgrades
Several brokerages recently commented on STIM. Weiss Ratings reissued a "sell (e+)" rating on shares of Neuronetics in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of Neuronetics from a "sell" rating to a "hold" rating in a research note on Saturday, December 6th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $7.00.
Check Out Our Latest Stock Analysis on Neuronetics
Hedge Funds Weigh In On Neuronetics
Several hedge funds and other institutional investors have recently bought and sold shares of STIM. XTX Topco Ltd boosted its holdings in shares of Neuronetics by 992.6% during the 4th quarter. XTX Topco Ltd now owns 314,194 shares of the company's stock valued at $434,000 after acquiring an additional 285,438 shares during the last quarter. Caption Management LLC lifted its position in Neuronetics by 571.4% during the fourth quarter. Caption Management LLC now owns 92,501 shares of the company's stock valued at $128,000 after purchasing an additional 78,723 shares during the period. Bridgeway Capital Management LLC boosted its holdings in Neuronetics by 35.6% in the fourth quarter. Bridgeway Capital Management LLC now owns 95,205 shares of the company's stock worth $131,000 after purchasing an additional 25,000 shares during the last quarter. FourWorld Capital Management LLC grew its position in Neuronetics by 64.0% in the 4th quarter. FourWorld Capital Management LLC now owns 931,250 shares of the company's stock worth $1,285,000 after purchasing an additional 363,250 shares during the period. Finally, Abel Hall LLC purchased a new stake in Neuronetics during the 4th quarter valued at $39,000. Institutional investors own 53.59% of the company's stock.
Neuronetics Company Profile
(
Get Free Report)
Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company's flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.
Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
